DDInter519 DDInter1435
Dexlansoprazole is a new-generation proton pump inhibitor (PPI) used for the management of symptoms associated with gastroesophageal reflux disease (GERD) and erosive esophagitis. Dexlansoprazole is the R-enantiomer of, which is composed of a racemic mixture of the R- and S-enantiomers. Compared to the older generation of PPIs (which includes,, and ), dexlansoprazole has a unique pharmacokinetic profile due to its delayed-release and dual-delivery release system: This aims to address some limitations of the older-generation PPIs, such as short plasma half-life and the need for meal-associated dosing.[A19566, A19568, A178084, A174244] Dexlansoprazole inhibits the final step in gastric acid production by blocking the (H+, K+)-ATPase enzyme.
Pexidartinib is a selective tyrosine kinase inhibitor that works by inhibiting the colony-stimulating factor (CSF1)/CSF1 receptor pathway. Pexidartinib was originally developed by Daiichi Sankyo, Inc. and it was approved by the FDA in August 2019 as the first systemic therapy for adult patients with symptomatic tenosynovial giant cell tumor. Tenosynovial giant cell tumor is a rare form of non-malignant tumor that causes the synovium and tendon sheaths to thicken and overgrow, leading to damage in surrounding joint tissue.[A182240,L7901] Debilitating symptoms often follow with tenosynovial giant cell tumors, along with a risk of significant functional limitations and a reduced quality of life in patients. While surgical resection is a current standard of care for tenosynovial giant cell tumor, there are tumor types where surgeries are deemed clinically ineffective with a high risk of lifetime recurrence. Pexidartinib works by blocking the immune responses that are activated in tenosynovial giant cell tumors. In clinical trials, pexidartinib was shown to promote improvements in patient symptoms and functional outcomes in TGCT. Pexidartinib is available in oral formulations and it is commonly marketed as Turalio.
Dexlansoprazole {u} may cause a minor interaction that can limit clinical effects when taken with {v} Prasugrel
Dexlansoprazole {u} may cause a minor interaction that can limit clinical effects when taken with {v} Acetylsalicylic acid
Dexlansoprazole {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Cisplatin
Dexlansoprazole {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Plazomicin
Dexlansoprazole {u} may lead to a major life threatening interaction when taken with {v} Methotrexate
Dexlansoprazole {u} may lead to a major life threatening interaction when taken with {v} Neratinib
Dexlansoprazole may cause a minor interaction that can limit clinical effects when taken with Prasugrel
Dexlansoprazole may cause a minor interaction that can limit clinical effects when taken with Acetylsalicylic acid
Dexlansoprazole may cause a moderate interaction that could exacerbate diseases when taken with Cisplatin
Dexlansoprazole may cause a moderate interaction that could exacerbate diseases when taken with Plazomicin
Dexlansoprazole may lead to a major life threatening interaction when taken with Methotrexate
Dexlansoprazole may lead to a major life threatening interaction when taken with Neratinib